Matthew W Johnson1, R Andrew Sewell, Roland R Griffiths. 1. Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, Behavioral Biology Research Center, Baltimore, MD 21224-6823, USA. mwj@jhu.edu
Abstract
BACKGROUND:Psilocybin is a well-characterized classic hallucinogen (psychedelic) with a long history of religious use by indigenous cultures, and nonmedical use in modern societies. Although psilocybin is structurally related to migraine medications, and case studies suggest that psilocybin may be efficacious in treatment of cluster headache, little is known about the relationship between psilocybin and headache. METHODS: This double-blind study examined a broad range of psilocybin doses (0, 5, 10, 20, and 30 mg/70 kg) on headache in 18 healthy participants. RESULTS:Psilocybin frequently caused headache, the incidence, duration, and severity of which increased in a dose-dependent manner. All headaches had delayed onset, were transient, and lasted no more than a day after psilocybin administration. CONCLUSIONS: Possible mechanisms for these observations are discussed, and include induction of delayed headache through nitric oxide release. These data suggest that headache is an adverse event to be expected with the nonmedical use of psilocybin-containing mushrooms as well as the administration of psilocybin in human research. Headaches were neither severe nor disabling, and should not present a barrier to future psilocybin research.
RCT Entities:
BACKGROUND:Psilocybin is a well-characterized classic hallucinogen (psychedelic) with a long history of religious use by indigenous cultures, and nonmedical use in modern societies. Although psilocybin is structurally related to migraine medications, and case studies suggest that psilocybin may be efficacious in treatment of cluster headache, little is known about the relationship between psilocybin and headache. METHODS: This double-blind study examined a broad range of psilocybin doses (0, 5, 10, 20, and 30 mg/70 kg) on headache in 18 healthy participants. RESULTS:Psilocybin frequently caused headache, the incidence, duration, and severity of which increased in a dose-dependent manner. All headaches had delayed onset, were transient, and lasted no more than a day after psilocybin administration. CONCLUSIONS: Possible mechanisms for these observations are discussed, and include induction of delayed headache through nitric oxide release. These data suggest that headache is an adverse event to be expected with the nonmedical use of psilocybin-containing mushrooms as well as the administration of psilocybin in human research. Headaches were neither severe nor disabling, and should not present a barrier to future psilocybin research.
Authors: Matthew W Johnson; Roland R Griffiths; Peter S Hendricks; Jack E Henningfield Journal: Neuropharmacology Date: 2018-06-05 Impact factor: 5.250
Authors: Chad J Reissig; Lawrence P Carter; Matthew W Johnson; Miriam Z Mintzer; Margaret A Klinedinst; Roland R Griffiths Journal: Psychopharmacology (Berl) Date: 2012-04-13 Impact factor: 4.530
Authors: Bruce E Blough; Antonio Landavazo; Ann M Decker; John S Partilla; Michael H Baumann; Richard B Rothman Journal: Psychopharmacology (Berl) Date: 2014-05-07 Impact factor: 4.530